Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.
The fight against the novel coronavirus pneumonia (namely COVID-19) that seriously harms human health is a common task for all mankind. Currently, development of drugs against the novel coronavirus (namely SARS-CoV-2) is quite urgent. Chinese medical workers and scientific researchers have found some drugs to play potential therapeutic effects on COVID-19 at the cellular level or in preliminary clinical trials. However, more fundamental studies and large sample clinical trials need to be done to ensure the efficacy and safety of these drugs. The adoption of these drugs without further testing must be careful. The relevant articles, news, and government reports published on the official and Preprint websites, PubMed and China National Knowledge Infrastructure (CNKI) databases from December 2019 to April 2020 were searched and manually filtered. The general pharmacological characteristics, indications, adverse reactions, general usage, and especially current status of the treatment of COVID-19 of those potentially effective drugs, including chemical drugs, traditional Chinese medicines (TCMs), and biological products in China were summarized in this review to guide reasonable medication and the development of specific drugs for the treatment of COVID-19.
['Pan|Xiaoqi|X|', 'Dong|Lan|L|', 'Yang|Lian|L|', 'Chen|Dayi|D|', 'Peng|Cheng|C|']
D000249:Adenosine Monophosphate D000409:Alanine D000577:Amides D000998:Antiviral Agents D000073640:Betacoronavirus D000086382:COVID-19 D002681:China D002738:Chloroquine D018352:Coronavirus Infections D004338:Drug Combinations D004365:Drugs, Chinese Herbal D006801:Humans D007211:Indoles D007372:Interferons D061466:Lopinavir D008168:Lung D058873:Pandemics D011024:Pneumonia, Viral D011719:Pyrazines D012254:Ribavirin D019438:Ritonavir D000086402:SARS-CoV-2 D016019:Survival Analysis
COVID-19 SARS-CoV-2 Chemical drugs Traditional Chinese medicines Biological products